GRML

Business Context and Reporting Period

Company: Klotho Neurosciences, Inc. (formerly ANEW Medical, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: The Company is a pre-revenue biopharmaceutical entity developing essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. Its portfolio includes a generic drug platform, a biosimilar biologics platform, and a proprietary gene therapy platform targeting the "Klotho" protein. The Company completed a reverse merger with Redwoods Acquisition Corp. in June 2024 and changed its legal name to Klotho Neurosciences, Inc. in September 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Remained at $0 for both the three and six-month periods ended June 30, 2025, consistent with the prior year periods.
• Net Loss: Net loss increased significantly to $4.09 million for the three months ended June 30, 2025, compared to $0.45 million in the same period in 2024. For the six months, the loss grew to $6.33 million from $1.12 million.
• Operating Expenses: Increased to $1.89 million (Q2) and $3.48 million (YTD) in 2025, driven by higher professional fees, general and administrative costs, share-based compensation, and the commencement of research and development (R&D) activities ($238,700 in Q2 2025 vs. $0 in Q2 2024).
• Other Expenses: Significant non-operating losses were recorded, including $1.76 million in interest expense for Q2 2025 (vs. $15k in Q2 2024) and a $331,546 loss on debt conversion. These were largely due to the amortization of original issue discounts (OID) and deferred financing costs on convertible notes.
• Liquidity: Cash and cash equivalents surged from $63,741 at December 31, 2024, to $8.43 million at June 30, 2025. This increase was primarily funded by financing activities, including warrant exercises ($11.4 million gross proceeds), stock subscriptions, and convertible note proceeds.
• Debt: The Company paid off all outstanding notes payable to related parties and third parties (including Austria Capital and 3i LP notes) by June 30, 2025, resulting in $0 notes payable on the balance sheet, down from $271,753 in total notes payable at year-end 2024.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for twelve months from the filing date without additional funding. The Company relies on equity or debt sales to fund operations.
• Unusual Items:
  • Warrant Modification: In Q2 2025, the Company reduced the exercise price of certain warrants from $3.49 to $1.35, recording a deemed dividend of approximately $1.53 million in accumulated deficit.
  • Debt Conversions: Significant portions of convertible debt were converted into equity during the period, triggering large non-cash interest expenses and losses on conversion.
• Risks and Contingencies:
  • NASDAQ Compliance: The Company received notices of non-compliance with minimum bid price and market value requirements in late 2024. However, the Company regained compliance with Nasdaq listing rules as of July 14, 2025, and its stock was approved to "phase down" to the Nasdaq Capital Market.
  • Internal Controls: Management identified material weaknesses in internal controls over financial reporting due to inadequate accounting resources and lack of segregation of duties.
  • Legal Proceedings: No material legal proceedings are currently pending.
• Subsequent Events:
  • Received Orphan Drug Designation from the FDA for its KLTO-202 gene therapy candidate for ALS (July 3, 2025).
  • Entered into an At-The-Market (ATM) sales agreement with A.G.P. for up to $50 million in equity (July 3, 2025).
  • Filed a Form S-3 registration statement for up to $100 million in securities (July 7, 2025).

Investor Verification Checklist

• Cash Runway: Verify the burn rate against the $8.4 million cash balance to assess the timeline for the next capital raise.
• Dilution Impact: Review the impact of recent warrant exercises, debt conversions, and the new ATM facility on existing shareholder ownership.
• NASDAQ Status: Confirm the Company's continued compliance with Nasdaq Capital Market listing requirements following the "phase down."
• Internal Controls: Monitor progress in remedying the material weaknesses in internal controls over financial reporting.
• Debt Obligations: Confirm that all convertible notes and related interest/OID obligations have been fully settled or converted as reported.
• Regulatory Milestones: Track the progress of the KLTO-202 gene therapy following the Orphan Drug Designation.